3Q PREVIEW: GSK, Lilly, BMS, Biogen and Celgene
This article was originally published in Scrip
Executive Summary
While the M&A train continued to come off the rails, the big pharma earnings season kicked off on 14 October with Johnson & Johnson reporting stronger than expected results thanks to brisk sales of its HCV shooting star Olysio (simeprevir) (scripintelligence.com, 15 October 2014), followed by Roche revealing upbeat sales as its breast cancer franchise performed well (scripintelligence.com, 16 October).